Covance says investor lawsuit seeking to derail LabCorp acquisition ‘without merit’

By Zachary Brennan contact

- Last updated on GMT

Covance calls investor suit seeking to derail acquisition meritless

Related tags: Goldman sachs, Covance

A Covance investor is raising questions over Goldman Sachs’ involvement in providing advice to the CRO’s board, which recently accepted a $6.1bn takeover offer from industry peer LabCorp.

Investor Barry Berk said in a Delaware Chancery Court lawsuit​ that Covance’s Board of Directors should not have hired Goldman Sachs as an adviser for LabCorp’s $105-a-share offer because of a conflict of interest as the investment firm already represented another company Covance was considering acquiring, according to Bloomberg News​.

But Melissa Thompson, spokeswoman for Covance, told “Covance believes this claim is without merit and intends to defend it vigorously​.”

Berk also claims that the deal undervalues Covance, which has seen its stock bounce above $100 per share since the deal was announced, according to the Shareholders Foundation. But analyst Ross Muken of ISI was positive​ on the deal when it was first announced, noting that Covance management “was smart to monetize a large portion of the equity given peak valuation levels​.”

Berk further claims that Goldman’s insistence that Covance accept the offer shows that it “succeeded in maximizing its own interests and the fees it can attain​.” Berk contends that Goldman would make upwards of $40m from the deal, which is designed to broaden LabCorp’s base and provide it with new revenue streams.

In his suit, Berk claims Covance’s board failed to properly shop the drug-testing company around for the highest bidder and relied on tainted advice from Goldman Sachs in accepting LabCorp’s offer.

Covance directors originally sought to hire Goldman Sachs to help it market the company after getting an offer from an unidentified company, but the New York firm was already representing a firm Covance was considering buying, according to the suit.

Covance directors then hired Citigroup bankers to be financial advisers on the potential acquisition of another unidentified firm, Berk said in the complaint. He is asking a judge to block the deal from proceeding until Covance and LabCorp officials make additional disclosures about the deal.

Bloomberg News notes that Goldman has faced criticism in the past about its management of potential conflicts of interest. The firm moved in September to bar investment bankers from trading individual stocks and bonds, a person familiar with the policy change told Bloomberg.

Related news

Show more

Related products

show more

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

Related suppliers

Follow us


View more